MX2023001418A - Forma sólida de compuesto. - Google Patents

Forma sólida de compuesto.

Info

Publication number
MX2023001418A
MX2023001418A MX2023001418A MX2023001418A MX2023001418A MX 2023001418 A MX2023001418 A MX 2023001418A MX 2023001418 A MX2023001418 A MX 2023001418A MX 2023001418 A MX2023001418 A MX 2023001418A MX 2023001418 A MX2023001418 A MX 2023001418A
Authority
MX
Mexico
Prior art keywords
compound
solid form
solvate
salt
mixture
Prior art date
Application number
MX2023001418A
Other languages
English (en)
Inventor
Zaiqi Wang
Jing Gao
Yingxia Sang
Original Assignee
Inxmed Nanjing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inxmed Nanjing Co Ltd filed Critical Inxmed Nanjing Co Ltd
Publication of MX2023001418A publication Critical patent/MX2023001418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona una forma sólida de un compuesto de fórmula (I) o una sal del mismo, o un solvato del mismo, o un solvato de una sal del mismo, o una mezcla de los mismos. (Ver Formula I).
MX2023001418A 2020-08-03 2021-08-02 Forma sólida de compuesto. MX2023001418A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010768730 2020-08-03
CN202010837005 2020-08-19
PCT/CN2021/110069 WO2022028367A1 (zh) 2020-08-03 2021-08-02 化合物的固体形式

Publications (1)

Publication Number Publication Date
MX2023001418A true MX2023001418A (es) 2023-04-10

Family

ID=80119956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001418A MX2023001418A (es) 2020-08-03 2021-08-02 Forma sólida de compuesto.

Country Status (13)

Country Link
US (2) US20230278985A1 (es)
EP (1) EP4190774A4 (es)
JP (1) JP2023536491A (es)
KR (1) KR20230048089A (es)
CN (1) CN116096713A (es)
AU (1) AU2021323235A1 (es)
BR (1) BR112023001962A2 (es)
CA (1) CA3188244A1 (es)
CL (1) CL2023000313A1 (es)
MX (1) MX2023001418A (es)
PE (1) PE20231303A1 (es)
TW (1) TW202206425A (es)
WO (1) WO2022028367A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118574825A (zh) * 2022-02-28 2024-08-30 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
WO2023246869A1 (zh) * 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
KR20210145175A (ko) * 2019-03-28 2021-12-01 앰플리아 테라퓨틱스 리미티드 Fak 억제제의 염 및 결정 형태
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
CA3158585A1 (en) * 2019-11-18 2021-05-27 Inxmed (Nanjing) Co., Ltd. Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
EP4066837A4 (en) * 2019-11-28 2023-12-06 Inxmed (Nanjing) Co., Ltd. USE OF BI853520 IN THE TREATMENT OF CANCER
CN115279376A (zh) * 2020-01-31 2022-11-01 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
CN115052603B (zh) * 2020-02-05 2023-12-19 应世生物科技(南京)有限公司 Bi853520与化疗药物的联用

Also Published As

Publication number Publication date
CL2023000313A1 (es) 2023-07-28
BR112023001962A2 (pt) 2023-04-11
PE20231303A1 (es) 2023-08-24
EP4190774A1 (en) 2023-06-07
US20240051942A1 (en) 2024-02-15
US11999719B2 (en) 2024-06-04
JP2023536491A (ja) 2023-08-25
AU2021323235A1 (en) 2023-03-02
US20230278985A1 (en) 2023-09-07
CN116096713A (zh) 2023-05-09
WO2022028367A1 (zh) 2022-02-10
EP4190774A4 (en) 2024-01-17
KR20230048089A (ko) 2023-04-10
CA3188244A1 (en) 2022-02-10
TW202206425A (zh) 2022-02-16

Similar Documents

Publication Publication Date Title
MX2022011283A (es) Compuestos pirimidoheterocíclicos y aplicación de los mismos.
MX2022007969A (es) Inhibidores de egfr.
MX2023009278A (es) Compuestos ciclicos aromaticos pirimidina.
CR20210032A (es) Compuestos
PH12021550400A1 (en) Cardiac sarcomere inhibitors
MX2023001418A (es) Forma sólida de compuesto.
MX2021013531A (es) Inhibidores de cdk.
ZA202000411B (en) Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2022004127A (es) Compuestos heterociclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
MX2021004386A (es) Compuestos novedosos.
MX2022004168A (es) Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3.
MX2023012477A (es) Compuestos heterociclicos.
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
MX2024005066A (es) Compuestos de cd73.
JOP20220085A1 (ar) مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر
WO2020003272A8 (en) An improved process for the preparation of venetoclax
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
MX2021009752A (es) Derivado de 7h-pirrolo[2,3-d]pirimidin-4-amina.
EP4289844A3 (en) A process for making palbociclib
CR20230555A (es) Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
MX2023002525A (es) Nuevos compuestos.
MX2022004178A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.